Lin Chen-Chun, Cheng Ya-Ting, Chen M Wei-Ting, Lin Shi-Ming
Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Lin-Kuo, Chang Gung University, Taoyuan, Taiwan.
Liver Cancer. 2016 Feb;5(1):8-20. doi: 10.1159/000367755. Epub 2015 Dec 15.
Outcomes of hepatocellular carcinoma (HCC) lesions >3.0 cm in size including Barcelona Clinic Liver Cancer (BCLC) stage B after radiofrequency ablation (RFA) with a single electrode remain unsatisfactory. This study aimed to investigate the outcomes of RFA with multiple electrodes (ME-RFA) for HCC tumors 3.1-7.0 cm in size and BCLC stage B. This retrospective study included 70 consecutive patients with 58 medium- (3.1-5.0 cm) and 17 large- (5.1-7.0 cm) sized HCCs after ME-RFA using a controller. Outcomes in terms of complete response, primary technique effectiveness, local tumor progression, and overall survival were investigated. After 1-4 applications of ME-RFA, the rates of complete response and PTE in medium-sized tumors were 79.3% and 91.4%, respectively, and in large tumors were 76.5% and 94.1%, respectively. Overall, the major complication rate was 5.7%. After a median 21-month follow-up period, both two- and three-year estimated overall survival rates were above 80%. There were no significant differences in overall survival and local tumor progression rates between medium- and large-size tumors and among BCLC stages A, B1 and B2. A complete response to ME-RFA was the only significant factor associated with improved survival (p=0.008). In conclusion, ME-RFA can effectively treat 3.1-7.0-cm sized HCCs with a comparable outcome between medium- and large-size tumors and among BCLA stages A to B2.
对于大小>3.0 cm的肝细胞癌(HCC)病变,包括巴塞罗那临床肝癌(BCLC)分期为B期的病变,采用单电极射频消融(RFA)的治疗效果仍不尽人意。本研究旨在探讨多电极RFA(ME-RFA)治疗大小为3.1 - 7.0 cm且BCLC分期为B期的HCC肿瘤的疗效。这项回顾性研究纳入了70例连续患者,这些患者使用控制器接受ME-RFA治疗,其中有58个中等大小(3.1 - 5.0 cm)和17个大尺寸(5.1 - 7.0 cm)的HCC。研究了完全缓解、主要技术有效性、局部肿瘤进展和总生存率等方面的结果。在进行1 - 4次ME-RFA治疗后,中等大小肿瘤的完全缓解率和主要技术有效性分别为79.3%和91.4%,大尺寸肿瘤分别为76.5%和94.1%。总体而言,主要并发症发生率为5.7%。经过中位21个月的随访期,两年和三年的估计总生存率均高于80%。中等大小和大尺寸肿瘤之间以及BCLC分期A、B1和B2之间的总生存率和局部肿瘤进展率没有显著差异。对ME-RFA的完全缓解是与生存率提高相关的唯一显著因素(p = 0.008)。总之,ME-RFA可以有效治疗大小为3.1 - 7.0 cm的HCC,中等大小和大尺寸肿瘤之间以及BCLA分期A至B2之间的疗效相当。